|
|
|
|
Thrice-daily was more effective than twice-daily administration of octreotide,and dose increments above 100 ug thrice daily did not confer additional benefit.Biochemical remission was achieved in 40%of patients and was dependent on the GH concentration at initiation of treatment. Cholelithiasis is a risk of octreotide therapy.Octreotide is effective and can be considered as a first-line therapy in patients with acromegaly with mean pretherapy GH concentrations below 20 mIU/L.In patients with mean GH over 20 mIU/L,octreotide may be used as an adjuvant to surgery or radiotherapy. |
|